Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Urine CartiLaps® ELISA (CTX-II)

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:C-terminal telopeptide II, carboxy-terminal collagen II crosslinks
Please select your region to see available products and prices.
Cat. No. Size Price


AC-10F1 96 wells
PubMed Product Details
Technical Data

Type

Competitive ELISA, Immobilized antigen

Description

The Urine CartiLaps® (CTX-II) EIA detects degradation products of C-terminal telopeptides of type II collagen. It is intended for in-vitro diagnostic use as an indication of degradation of cartilage and may be used as an aid for:

  • Quantitative assessment of disease activity (structural damage of articular cartilage) in patients with RA and OA.
  • Prognosis of disease activity in patients with RA and OA, and early assessment of long-term effect of therapy in patients with RA.

Scientific Description:

Disruption of the structural integrity of cartilage is the major histological finding in osteoarthritis and rheumatoid arthritis. Type II collagen is the major organic constituent of cartilage. Fragments of type II collagen (CTX-II) are being released into circulation and subsequently secreted into urine following degradation of cartilage. In urine, the CTX-II fragments can be quantified by Urine CartiLaps® (CTX-II) EIA. The Urine CartiLaps® (CTX-II) EIA has been reported to be useful in prediction of the progression of osteoarthritis (Reijman et al., Garnero et al), and in other clinical (Rotterud) and pre-clinical investigations.

Applications

Urine

Sample Requirements

40 µL/well

Storage/Expiration

Store the complete kit at 2-8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0-10 ng/mL

Limit of Detection

0.20 μg/L

Summary

Features

  • Quantitative assessment of disease activity (structural damage of articular cartilage) in patients with RA and OA
  • Prognosis of disease activity in patients with RA and OA
  • Early assessment of long-term effect of therapy in patients with RA
  • Excellent correlation to immunohistochemistry and imaging techniques

Research topic

Bone and cartilage metabolism

Product References (1)

References

  • Henrotin Y, Bannuru R, Malaise M, Ea HK, Confavreux C, Bentin J,Urbin-Choffray D, Conrozier T, Brasseur JP, Thomas P, Hick AC, Marinello A,Giordan N, Richette P. Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study. BMCMusculoskelet Disord. 2019 Jun 18;20(1):293. doi: 10.1186/s12891-019-2667-0.PubMed PMID: 31215422; PubMed Central PMCID: PMC6580647. See more on PubMed
Related Products Docs